SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is gaining significant market attention as traders react to major quantum executive orders, ongoing Russell 3000 index inclusion momentum, and a series of high-profile government-linked events. The community is actively debating the company's valuation versus peers and discussing its long-term potential as a key player in the quantum computing and sensing space.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently facing intense selling pressure as it hits new 52-week lows, with market sentiment heavily divided between those who view the decline as a valuation reset and others who see it as a bearish breakdown of its long-term technical structure. Community discussion is dominated by heated debates regarding institutional accumulation versus retail capitulation, fueled by reports of contract shifts in Europe and skepticism toward the stock's high valuation multiples compared to its growth trajectory.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. is trending as investors weigh potential government funding and strategic interest in quantum infrastructure against concerns regarding heavy insider selling and high cash-burn rates. The community remains polarized, with bulls pointing toward the company's dual-platform technology as a catalyst for long-term growth, while bears continue to scrutinize the stock's valuation relative to its revenue and recent insider activity.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is drawing significant investor interest as shareholders look for a potential turnaround driven by new leadership and international expansion efforts, despite ongoing concerns over short interest and competitive pressures. The community remains divided, with some betting on a buyout catalyst or short squeeze while others highlight operational frustrations and dividend sustainability.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is seeing heightened investor attention driven by strong momentum in the weight-loss peptide space and analyst upgrades that highlight its growth potential. The community is actively debating the company's long-term platform shift toward a broader healthcare ecosystem while keeping a close eye on the upcoming FDA advisory meeting as a potential fundamental catalyst.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is facing downward pressure amid broader hyperscaler concerns over AI infrastructure spending, with investors closely watching Prime Day as a gauge for consumer health. While the community is debating the stock's valuation versus its massive capital expenditure, many remain focused on the long-term potential of AWS and the company's aggressive push into custom AI silicon.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending following the disappointing Phase 3 trial results for its cancer drug sigvotatug vedotin, alongside concerns regarding ongoing leadership transitions. The community remains deeply divided, with some expressing frustration over recent pipeline setbacks and management's strategic direction, while others continue to view the stock as a value-based, long-term dividend opportunity.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. (QUBT) is surging alongside the broader quantum sector following a major government push for quantum innovation, which has renewed investor interest in hardware and infrastructure plays. The community is actively debating the potential for a short squeeze, citing high short interest and institutional interest as investors track which companies can successfully move from research phases to scalable, real-world commercial deployment.

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics (DFTX) is trending following positive Phase 3 clinical trial results for its depression treatment, triggering a surge in trading volume and investor attention. While some community members celebrate the potential for this breakthrough to reshape mental health care, others remain cautious, expressing significant concerns about the company's historical financial practices, high cash burn rate, and the risk of shareholder dilution.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is experiencing heightened volatility and trading volume as investors await imminent clinical trial event milestones, driving intense debate between bullish retail traders anticipating a potential short squeeze and skeptical market participants citing regulatory and financial risks. The stock's elevated cost-to-borrow fees and high short interest have intensified community discourse regarding the potential for an acquisition or significant valuation shift following the upcoming data readout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Top 3 Health Care Stocks You'll Regret Missing In Q2

Health care sector's oversold stocks present buying opportunity; RSI below 30 signals oversold, according to Benzinga Pro. iRhythm, Procept Biorobotics, Anbio Biotechnology among lowest RSI values.read more...

Anbio Biotechnology (NASDAQ:NNNN) Shares Up 11.6% - Time to Buy?

Anbio Biotechnology (NASDAQ:NNNN) Trading Up 11.6% - What's Next...

Anbio Biotechnology (NASDAQ:NNNN) Shares Gap Down   - Should You Sell?

Anbio Biotechnology (NASDAQ:NNNN) Shares Gap Down - Should You Sell...

Anbio Biotechnology (NASDAQ:NNNN) Trading Down 5.5% - Here's What Happened

Anbio Biotechnology (NASDAQ:NNNN) Trading Down 5.5% - Here's Why...

Anbio Biotechnology Posts Solid FY25 Results, Diversifies Portfolio

Anbio Biotechnology reported strong 2025 results with sales of $8.65M. The company is diversifying away from COVID products.read more...

Anbio Biotechnology (NASDAQ:NNNN) Shares Up 4.4%  - Still a Buy?

Anbio Biotechnology (NASDAQ:NNNN) Trading Up 4.4% - Still a Buy...

Anbio Biotechnology (NASDAQ:NNNN) Shares Gap Up - Still a Buy?

Anbio Biotechnology (NASDAQ:NNNN) Shares Gap Up - What's Next...

Anbio Biotechnology (NASDAQ:NNNN) Stock Price Up 5.6% - Still a Buy?

Anbio Biotechnology (NASDAQ:NNNN) Trading 5.6% Higher - Here's What Happened...

Anbio Biotechnology (NASDAQ:NNNN) Shares Gap Up   - Still a Buy?

Anbio Biotechnology (NASDAQ:NNNN) Shares Gap Up - Still a Buy...

Anbio Biotechnology (NASDAQ:NNNN) Shares Gap Down   - Time to Sell?

Anbio Biotechnology is a medical device company. It is focused on developing and manufacturing a range of in-vitro diagnostic (IVD) products. The company was founded on July 27, 2021 and is headquartered in Frankfurt, Germany.

Anbio Biotechnology - Ordinary Shares - Class A

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

NNNNAnbio Biotechnology

Latest NNNN News